The FDA granted full approval to Precigen's Papzimeos, a non-replicating adenoviral vector immunotherapy targeting human papillomavirus (HPV) types 6 and 11 to treat recurrent respiratory papillomatosis (RRP), a rare condition causing recurrent airway tumors. Clinical results demonstrated significant reductions in surgical interventions post-treatment. This marks the first approved systemic treatment for RRP, offering a vaccine-based therapeutic approach for patients with persistent HPV infection not addressed by current preventive vaccines.